Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | EDNRB | P24530 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462636 | 1.00 | BCAT2 (0.55) | BCAT2RIPK1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL5470948 | 1.00 | BCAT2 (0.55) | BCAT2RIPK1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL8021780 | 0.92 | BCAT2 (0.55) | BCAT2RIPK1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL2091811 | 0.83 | HRH1 (0.52) | SMN1; SMN2CYP1A2CYP2D6PKMNPSR1 | |
| SCHEMBL258372 | 0.83 | RIPK1 (0.52) | BCAT2RIPK1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL991988 | 0.83 | RIPK1 (0.52) | BCAT2RIPK1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL8107873 | 0.83 | RIPK1 (0.52) | BCAT2RIPK1SMN1; SMN2CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28569021 | 0.82 | HRH1 (0.50) | SMN1; SMN2CYP1A2CYP2D6PKMNPSR1 | |
| SCHEMBL28957129 | 0.81 | AOC3 (0.47) | AOC3KDM4E | |
| SCHEMBL22190392 | 0.81 | BCAT2 (0.36) | BCAT2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114850480-A | Preparation method of high-conductivity flake silver powder for touch screen silver paste | 中船重工黄冈贵金属有限公司 | 2022-08-05 | — | — | CN | claimed |
| US-20030096019-A1 | Methods of using norfluoxetine | SEPRACOR INC. | 2003-05-22 | — | — | US | claimed |
| CN-116217415-B | Method for synthesizing chiral 3-amino-1-phenylpropanol and chiral 3- (methylamino) -1-phenylpropanol | 武汉大学 | 2024-06-18 | — | — | CN | disclosed |
| CN-114605272-B | Preparation method of (R) -fluoxetine and derivatives thereof | 中国科学技术大学 | 2023-09-08 | — | — | CN | disclosed |
| CN-116217415-A | Method for synthesizing chiral 3-amino-1-phenylpropanol and chiral 3- (methylamino) -1-phenylpropanol | 武汉大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-114850480-A | Preparation method of high-conductivity flake silver powder for touch screen silver paste | 中船重工黄冈贵金属有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114850480-A | Preparation method of high-conductivity flake silver powder for touch screen silver paste | 中船重工黄冈贵金属有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114605272-A | Preparation method of (R) -fluoxetine and derivative thereof | 中国科学技术大学 | 2022-06-10 | — | — | CN | disclosed |
| WO-2020141734-A1 | METHOD FOR PREPARING CHIRAL GAMMA-LACTAM COMPOUND AND METAL COMPLEX THEREFOR | 기초과학연구원 | 2020-07-09 | — | — | WO | disclosed |
| US-8163761-B2 | Methods and compositions for treating disorders | HYDRA BIOSCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20070078188-A1 | Compositions comprising and methods of using norfluoxetine | CURRIE MARK G | 2007-04-05 | — | — | US | disclosed |
| US-20030096019-A1 | Methods of using norfluoxetine | SEPRACOR INC. | 2003-05-22 | — | — | US | disclosed |
| US-6566375-B1 | For therapy of atherosclerosis | WYETH | 2003-05-20 | — | — | US | disclosed |
| US-6316467-B1 | Elevation of HDL cholesterol by 4-[(Aminothioxomethyl)-hydrazono]-N-(substituted)-4-arylbutanamides | AMERICAN HOME PRODUCTS CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6034272-A | CARDIOVASCULAR DISORDERS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-03-07 | — | — | US | disclosed |
| US-6028224-A | Fluoxetine process from benzoylpropionic acid | SEPRACOR INC. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999067196-A1 | FLUOXETINE PROCESS FROM BENZOYLPROPIONIC ACID | SEPRACOR INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5936124-A | Fluoxetine process from benzoylpropionic acid | SEPACOR INC. (US) | 1999-08-10 | — | — | US | disclosed |
| WO-1999025682-A1 | ELEVATION OF HDL CHOLESTEROL BY 4-[(AMINOTHIOXOMETHYL) -HYDRAZONO] -N-(SUBSTITUTED) -4-ARYLBUTANAMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1998057929-A1 | ELEVATION OF HDL CHOLESTEROL BY N-[4-[ (AMINOTHIOXOMETHYL) HYDRAZONO] -4-ARYLBUTYL]AMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096019-A1 | Methods of using norfluoxetine | NGF, TPH2, ALOX5 | BCAT2 1921/4885RIPK1 4867/4885SMN1; SMN2 752/4885 |
| US-20070078188-A1 | Compositions comprising and methods of using norfluoxetine | ALOX5, NGF, PTGER4 | BCAT2 1679/4885RIPK1 4861/4885SMN1; SMN2 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.